Top in cardiology: Wear Red Day for heart disease; secondary CVD prevention meds underused
Wear Red Day, the first Friday of February, draws attention to the prevalence and dangerousness of heart disease in women as part of American Heart Month.
Heart disease is the leading cause of death among women, but symptoms can often go unreported, and women are underrepresented in cardiology clinical trials.
Healio received the opinions of several experts on this topic, including what they believe are some of the most urgent issues related to heart disease. It was the top story in cardiology last week.
In another top story, researchers found that many patients in need of medications for the secondary prevention of CVD did not receive them, even patients in high-income countries.
Read these and more top stories in cardiology below:
Heart disease remains the No. 1 cause of death in women: Why?
February is American Heart Month, a highlight of which is Wear Red Day, which aims to raise awareness about heart disease in women, on the first Friday of the month. Read more.
Medications for secondary CVD prevention underused worldwide
Regardless of country-level income classification, medications for the secondary prevention of CVD remains underutilized and patients likely remain undertreated, researcher reported. Read more.
COVID-19-causing virus linked to coronary plaque progression, risk for MI, death
SARS-CoV-2 infection was associated with more rapid coronary plaque progression and significantly increased risk for adverse outcomes related to target lesion failure, such as heart attack and death, researchers reported. Read more.
‘Alarming gaps in knowledge’: Exploring the intersection of reproductive health and the heart
Recent research reported that women with endometriosis have an approximately 20% increased risk for stroke and a 35% greater risk for heart attack compared with women without endometriosis. Read more.
FDA clears first assay designed to measure lipoprotein(a) in nanomoles
Roche announced its next generation assay received FDA 510(k) clearance for the measurement of lipoprotein(a) for assessment of cardiovascular risk. Read more.